How This Works
Semax is a synthetic analog of the ACTH(4–10) fragment with a C‑terminal Pro‑Gly‑Pro tripeptide extension that enhances metabolic stability. Clinical and preclinical literature suggest it modulates brain‑derived neurotrophic factor (BDNF) expression, enhances cholinergic and dopaminergic neurotransmission, and exhibits neuroprotective properties in models of cerebrovascular and cognitive impairment.
Human studies in Russia have employed Semax for cognitive support in conditions ranging from mild cognitive impairment to acute stroke recovery, typically using intranasal administration. Subcutaneous delivery offers an alternative route with potentially more sustained systemic absorption.
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
May support attention, memory consolidation, and learning in clinical populations with cognitive deficits.
Studied in neurological conditions including stroke, traumatic brain injury, and optic neuropathy with favorable safety profiles in month‑long human trials.
Generally well tolerated; intranasal administration may cause minor nasal irritation; subcutaneous injection may produce mild injection‑site reactions (redness, itching).
No significant elevations in cortisol or other adverse endocrine effects reported in clinical studies.
Effects are dose‑dependent; titration helps identify the minimum effective dose for individual response.
Disclaimer:
The information provided in this article is for educational and informational purposes only and is not intended as medical advice. These statements have not been evaluated by the FDA or Health Canada. Peptides and other compounds discussed are intended for research purposes only and are not approved for human consumption unless prescribed by a licensed medical professional. Always consult your healthcare provider before starting any new protocol, supplement, or treatment.